Deal Watch: Pfizer Offloads Troubled ADHD Products To Manufacturer Tris
Executive Summary
Tris acquires Pfizer subsidiary Nextwave, which developed pair of ADHD drugs using Tris delivery technology. Lilly gets oral CGRP candidate from Chugai, while Dova signs US co-promotion partner for Doptelet.
You may also be interested in...
Teva Fails On Quillivant XR Appeal – Five Years After Winning
Teva’s Actavis looks unlikely to be launching its proposed generic version of Tris Pharma’s Quillivant XR (methylphenidate) extended-release oral suspension soon, after a remanded district court decision that went against the firm was upheld on appeal.
Lilly Aims For Earlier Treatment With Novel Diabetes Drugs
Lilly outlined its tirzepatide-led pipeline of incretin agonists and highlighted its once-weekly basal insulin during a post-ADA event. The company hopes to grow the GLP-1 market overall rather than shift patients from Trulicity.
Finance Watch: New Funding Available For Antibacterials, Start-Ups
Private Company Edition: The Novo Holdings Repair Impact Fund wants to fund another round of antimicrobial resistance efforts. Also, Atlas Venture raised a new $400m fund, Everest closed a $310m series C round and Cognition received a $78.5m grant.